Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

LY2275796 in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: LY2275796

First Posted Date: 2009-05-18

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00903708

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Erlotinib Hydrochloride (Tarceva)

First Posted Date: 2009-05-18

Last Posted Date: 2015-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00903734

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Male:Female Birth Ratios and Phthalate Levels

Completed

Conditions: Endocrine Diseases

Interventions: Behavioral: Questionnaire

First Posted Date: 2009-05-18

Last Posted Date: 2017-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT00903318

Locations: 🇺🇸
Goose Creek Consolidated Independent School District, Baytown, Texas, United States
🇺🇸
Texas Southern University, Houston, Texas, United States
🇺🇸
LaJoya Independent School District, La Joya, Texas, United States

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Dasatinib
Drug: MK-0646

First Posted Date: 2009-05-15

Last Posted Date: 2015-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00903006

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Bendamustine
Drug: Mitoxantrone
Drug: Rituximab

First Posted Date: 2009-05-14

Last Posted Date: 2020-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00901927

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Urodynamics Test
Behavioral: Questionnaire

First Posted Date: 2009-05-13

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00901420

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Terminated

Conditions: Peritoneal Cavity Cancer
Ovarian Cancer

Interventions: Genetic: Microarray analysis
Other: Laboratory biomarker analysis

First Posted Date: 2009-05-12

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00897806

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab
Procedure: Stem Cell Transplantation
Drug: Thymoglobulin
Drug: Bendamustine
Drug: Allopurinol

First Posted Date: 2009-05-12

Last Posted Date: 2020-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00899431

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

Phase 1

Terminated

Conditions: Glioblastoma
CNS Disease
Brain Diseases

Interventions: Drug: Dasatinib
Radiation: RT (Radiotherapy)
Drug: TMZ (Temozolomide)

First Posted Date: 2009-05-11

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00895960

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Erlotinib in Combination With Bortezomib

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Erlotinib Hydrochloride
Drug: Bortezomib

First Posted Date: 2009-05-08

Last Posted Date: 2015-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00895687

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy